Login to Your Account



'Build to Buy' Model

Quanticel, Celgene and Versant Ink $45M Cancer Collaboration

By Tom Wall
BioWorld Today Contributing Writer

Monday, November 7, 2011

Quanticel Pharmaceuticals Inc., a fledgling, privately held San Francisco biotech, Celgene Corp., of Summit, N.J., and California venture capital firm Versant Ventures have agreed to a 3.5-year, $45 million "build to buy" cancer drug collaboration.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription